FibroGen Inc. (NASDAQ:FGEN)’s share price rose 2.2% during mid-day trading on Friday . The stock traded as high as $17.13 and last traded at $17.03, with a volume of 261,699 shares traded. The stock had previously closed at $16.66.

Several equities research analysts have weighed in on FGEN shares. Credit Suisse Group AG reaffirmed a “buy” rating and issued a $38.00 target price on shares of FibroGen in a research report on Tuesday, May 10th. Zacks Investment Research raised FibroGen from a “sell” rating to a “hold” rating in a research report on Tuesday, May 10th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. FibroGen currently has a consensus rating of “Buy” and a consensus price target of $33.50.

The firm’s market cap is $1.07 billion. The company’s 50-day moving average price is $17.14 and its 200 day moving average price is $19.22.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.56) by $0.11. On average, equities research analysts predict that FibroGen Inc. will post ($1.02) EPS for the current fiscal year.

In other FibroGen news, CEO Thomas B. Neff sold 27,000 shares of FibroGen stock in a transaction that occurred on Wednesday, June 29th. The stock was sold at an average price of $16.02, for a total value of $432,540.00. Following the transaction, the chief executive officer now directly owns 3,439,764 shares of the company’s stock, valued at approximately $55,105,019.28. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Thomas B. Neff sold 13,500 shares of FibroGen stock in a transaction that occurred on Tuesday, April 19th. The stock was sold at an average price of $20.21, for a total value of $272,835.00. Following the completion of the transaction, the chief executive officer now directly owns 3,579,353 shares in the company, valued at $72,338,724.13. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have modified their holdings of the company. Nationwide Fund Advisors increased its position in shares of FibroGen by 0.8% in the fourth quarter. Nationwide Fund Advisors now owns 51,597 shares of the biopharmaceutical company’s stock valued at $1,572,000 after buying an additional 393 shares in the last quarter. Swiss National Bank boosted its stake in FibroGen by 1.8% in the fourth quarter. Swiss National Bank now owns 63,400 shares of the biopharmaceutical company’s stock worth $1,932,000 after buying an additional 1,100 shares in the last quarter. California State Teachers Retirement System boosted its stake in FibroGen by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 88,701 shares of the biopharmaceutical company’s stock worth $2,703,000 after buying an additional 1,400 shares in the last quarter. Rhumbline Advisers boosted its stake in FibroGen by 8.7% in the fourth quarter. Rhumbline Advisers now owns 45,940 shares of the biopharmaceutical company’s stock worth $1,400,000 after buying an additional 3,675 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in FibroGen by 8,621.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 35,756 shares of the biopharmaceutical company’s stock worth $1,090,000 after buying an additional 35,346 shares in the last quarter.

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.